Halozyme Therapeutics Inc. logo

Halozyme Therapeutics Inc. (HALO)

Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
77. 81
+0.27
+0.3482%
$
9.04B Market Cap
20.87 P/E Ratio
- Div Yield
1.48M Volume
2.74 Eps
$ 77.54
Previous Close
Add Transaction
Day Range
77.17 79.56
Year Range
55.64 82.26
Want to track HALO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Halozyme Therapeutics Inc. (HALO) Statistics

Valuation metrics

Market Cap 9.04B
Enterprise value 11.06B
Trailing P/E (ttm) 26.65
Forward P/E 6.91
PEG ratio -1.1
Price/Sales (ttm) 6.12
Price/Book (mrq) 41.85
Enterprise Value/Revenue 7.33
Enterprise Value/EBITDA 17.74

Overview

Shares outstanding 118.52M
Float 117.28M
Shares short 14.38M
% Held by insiders 0.01%
% Held by institutions 1.08%
Average volume (10 days) 1.71M
Average volume (90 days) 1.74M

Price summary

52-Week low 55.64
52-Week high 82.26
Beta 0.88
50-Day moving average 75.1
200-Day moving average 69.71

Dividends and splits

Forward annual dividend rate -
Forward annual dividend yield -
Trailing annual dividend rate -
Trailing annual dividend yield -
5-Year annual dividend yield -
Payout ratio -
Dividend Date -
Ex-Dividend Date -
Last split factor 171:40
Last split Date 10 Dec 2003

Financials

Fiscal year

Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Mar 2026

Profitability

Profit margin 0.23%
Operating margin 0.57%

Operational effectiveness

Return on assets 0.13%
Return on equity 1.26%

Income Statement

Revenue (ttm) 1.51B
Revenue per share (ttm) 12.77
Quarterly revenue growth (yoy) 0.42%
Gross profit (ttm) 1.16B
EBITDA 946.91M
Net income to common (ttm) 348.84M
Diluted EPS (ttm) 2.95
Quarterly earnings growth (yoy) 0.27%

Balance Sheet

Total cash (mrq) 318.62M
Total cash per share (mrq) 2.7
Total debt (mrq) 2.18B
Total Debt/Equity (mrq) 9.76
Current ratio (mrq) 2.76%
Book value per share (mrq) 1.86

Cash Flow

Cash flow statement 677.41M
Levered free cash flow (LFCF) 228.12M